USA – Purple Book: FDA adds transition biologics as move to single database progresses

The US Food and Drug Administration (FDA) on Monday updated its searchable Purple Book database to include all biologics regulated by its Center for Drug Evaluation and Research (CDER) with the addition of products that transitioned from new drug applications (NDAs) to biologics license applications (BLAs) last March.

With the update, FDA also added the ability to download monthly reports that include a changelog detailing new and updated products from the previous month…